{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:06:45Z","timestamp":1789074405845,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004635","name":"Mrs Berta Kamprad Foundation for Research and Combating Cancer Diseases","doi-asserted-by":"publisher","award":["FBKS-2020-22- (291)"],"award-info":[{"award-number":["FBKS-2020-22- (291)"]}],"id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003549","name":"Hungarian Scientific Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Hungarian Scientific Research Fund","doi-asserted-by":"publisher","award":["K-147410"],"award-info":[{"award-number":["K-147410"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Hungarian Scientific Research Fund","doi-asserted-by":"publisher","award":["130356"],"award-info":[{"award-number":["130356"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Hungarian Scientific Research Fund","doi-asserted-by":"publisher","award":["TKP2021-EGA-44"],"award-info":[{"award-number":["TKP2021-EGA-44"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Hungarian Scientific Research Fund","doi-asserted-by":"publisher","award":["2021-1 . 2 . 4-T \\u00C9T-2021-00030"],"award-info":[{"award-number":["2021-1 . 2 . 4-T \\u00C9T-2021-00030"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Hungarian Scientific Research Fund","doi-asserted-by":"publisher","award":["2022-2.1.1-NL-2022-00010"],"award-info":[{"award-number":["2022-2.1.1-NL-2022-00010"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejphar.2026.179293","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T14:39:57Z","timestamp":1787409597000},"page":"179293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative assessment of intratumoral sunitinib distribution and therapeutic response in matched primary and metastatic tumor models"],"prefix":"10.1016","volume":"1033","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-2930","authenticated-orcid":false,"given":"Anna","family":"S\u00f3lyom-Tisza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3781-1312","authenticated-orcid":false,"given":"Szilvia","family":"T\u00f6r\u00f6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ron","family":"Gell\u00e9rt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edina","family":"Bugyik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Berta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0742-8707","authenticated-orcid":false,"given":"Ildik\u00f3","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8773-5760","authenticated-orcid":false,"given":"N\u00e1ndor","family":"B\u00e1r\u00e1ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Marko-Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"T\u00f3v\u00e1ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Sz\u0151ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Paku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"D\u00f6me","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Dezs\u0151","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikt\u00f3ria","family":"L\u00e1szl\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4373-5616","authenticated-orcid":false,"given":"Melinda","family":"Rezeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179293_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fonc.2013.00211","article-title":"Vascular permeability and drug delivery in cancers","volume":"3","author":"Azzi","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2026.179293_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.179293_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/218578","article-title":"Early monitoring antiangiogenesis treatment response of sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET\/CT imaging","volume":"2014","author":"Bao","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.ejphar.2026.179293_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081912","article-title":"Alternative vascularization mechanisms in tumor resistance to therapy","volume":"13","author":"Belotti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2026.179293_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature10908","article-title":"Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling","volume":"484","author":"Benedito","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179293_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13361-017-1809-6","article-title":"MSiReader v1.0: evolving open-source mass spectrometry imaging software for targeted and untargeted analyses","volume":"29","author":"Bokhart","year":"2018","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ejphar.2026.179293_bib7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/path.4845","article-title":"Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models","volume":"241","author":"Bridgeman","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejphar.2026.179293_bib8","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10549-012-2008-6","article-title":"Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial","volume":"133","author":"Brufsky","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2026.179293_bib9","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/NEN.0b013e318233afd7","article-title":"Lack of angiogenesis in experimental brain metastases","volume":"70","author":"Bugyik","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ejphar.2026.179293_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40880-016-0083-5","article-title":"Mechanisms of vascularization in murine models of primary and metastatic tumor growth","volume":"35","author":"Bugyik","year":"2016","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.179293_bib11","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/nbt.2377","article-title":"A cross-platform toolkit for mass spectrometry and proteomics","volume":"30","author":"Chambers","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2026.179293_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2045-824X-6-12","article-title":"Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells","volume":"6","author":"Chinchar","year":"2014","journal-title":"Vasc. Cell"},{"key":"10.1016\/j.ejphar.2026.179293_bib13","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","article-title":"Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy","volume":"55","author":"Choi","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejphar.2026.179293_bib14","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.breast.2013.07.037","article-title":"Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer","volume":"22","author":"Curigliano","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.ejphar.2026.179293_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2011.04.027","article-title":"Impact of hypoxia on the metastatic potential of human prostate cancer cells","volume":"81","author":"Dai","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejphar.2026.179293_bib16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1215\/15228517-2007-024","article-title":"Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma","volume":"9","author":"DE Bouard","year":"2007","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejphar.2026.179293_bib17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nrc.2017.93","article-title":"Transport of drugs from blood vessels to tumour tissue","volume":"17","author":"Dewhirst","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2026.179293_bib18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/cam4.105","article-title":"Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?","volume":"2","author":"Donnem","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejphar.2026.179293_bib19","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114850","article-title":"Advances in high-throughput mass spectrometry in drug discovery","volume":"15","author":"Duenas","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejphar.2026.179293_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2026.179293_bib21","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1073\/pnas.0812413106","article-title":"KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients","volume":"106","author":"Gajiwala","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2026.179293_bib22","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.21037\/jtd.2020.04.28","article-title":"The epidemiology and biology of pulmonary metastases","volume":"13","author":"Gerull","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ejphar.2026.179293_bib23","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/bioinformatics\/bts447","article-title":"MALDIquant: a versatile R package for the analysis of mass spectrometry data","volume":"28","author":"Gibb","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejphar.2026.179293_bib24","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006486","article-title":"Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease","volume":"2","author":"Goel","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejphar.2026.179293_bib25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00280-008-0917-1","article-title":"Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species","volume":"64","author":"Haznedar","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179293_bib26","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.179293_bib27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure - an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2026.179293_bib28","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1039\/D3CC05988J","article-title":"Quantitative mass spectrometry imaging: therapeutics & biomolecules","volume":"60","author":"Holbrook","year":"2024","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejphar.2026.179293_bib29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s43018-022-00353-6","article-title":"Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs","volume":"3","author":"Hongu","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejphar.2026.179293_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13058-019-1167-3","article-title":"Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer","volume":"21","author":"Hori","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179293_bib31","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1158\/0008-5472.CAN-09-3722","article-title":"Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma","volume":"70","author":"Huang","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179293_bib32","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-09-3965","article-title":"Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma","volume":"70","author":"Huang","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179293_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2026.179293_bib34","series-title":"Disclosure: Anup Kasi Declares No Relevant Financial Relationships with Ineligible Companies","article-title":"Lung Metastasis. StatPearls. Treasure Island (FL) ineligible companies","author":"Jamil","year":"2025"},{"key":"10.1016\/j.ejphar.2026.179293_bib35","article-title":"Pattern of pulmonary metastases in various malignancies","volume":"0","author":"Jogondra","year":"2025","journal-title":"Apollo Medicine"},{"key":"10.1016\/j.ejphar.2026.179293_bib36","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/bjc.2011.147","article-title":"Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases","volume":"104","author":"Jubb","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.179293_bib37","doi-asserted-by":"crossref","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: the DrugBank Knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2026.179293_bib38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41571-019-0181-9","article-title":"Vessel co-option in cancer","volume":"16","author":"Kuczynski","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.179293_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw030","article-title":"Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma","volume":"108","author":"Kuczynski","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejphar.2026.179293_bib40","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.addr.2013.04.009","article-title":"Qualitative and quantitative mass spectrometry imaging of drugs and metabolites","volume":"65","author":"Lietz","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2026.179293_bib41","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10637-016-0415-y","article-title":"Sunitinib-paracetamol sex-divergent pharmacokinetics and tissue distribution drug-drug interaction in mice","volume":"35","author":"Liew","year":"2017","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejphar.2026.179293_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2210-10-14","article-title":"Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice","volume":"10","author":"Lim","year":"2010","journal-title":"BMC Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179293_bib43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2026.179293_bib44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2026.179293_bib45","article-title":"Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0","volume":"18","author":"Percie Du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejphar.2026.179293_bib46","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1016\/S0959-8049(96)00377-2","article-title":"Angiogenesis in primary lung cancer and lung secondaries","volume":"32A","author":"Pezzella","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.179293_bib47","first-page":"1417","article-title":"Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis","volume":"151","author":"Pezzella","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2026.179293_bib48","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/jms.525","article-title":"Direct analysis of drug candidates in tissue by matrix-assisted laser desorption\/ionization mass spectrometry","volume":"38","author":"Reyzer","year":"2003","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.ejphar.2026.179293_bib49","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbapap.2016.12.011","article-title":"Quantification of low molecular weight compounds by MALDI imaging mass spectrometry - a tutorial review","volume":"1865","author":"Rzagalinski","year":"2017","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"10.1016\/j.ejphar.2026.179293_bib50","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejphar.2026.179293_bib51","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1515\/cclm-2019-0858","article-title":"Cellular resolution in clinical MALDI mass spectrometry imaging: the latest advancements and current challenges","volume":"58","author":"Scupakova","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.ejphar.2026.179293_bib52","doi-asserted-by":"crossref","first-page":"18632","DOI":"10.1073\/pnas.1318415110","article-title":"Combining two strategies to improve perfusion and drug delivery in solid tumors","volume":"110","author":"Stylianopoulos","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2026.179293_bib53","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/jm0204183","volume":"46","author":"Sun","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.179293_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00418-013-1127-4","article-title":"Qualitative and quantitative mass spectrometry imaging of drugs and metabolites in tissue at therapeutic levels","volume":"140","author":"Sun","year":"2013","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.ejphar.2026.179293_bib55","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/path.4464","article-title":"Mechanism of tumour vascularization in experimental lung metastases","volume":"235","author":"Szabo","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejphar.2026.179293_bib56","series-title":"Disclosure: Yasmyne Ronquillo Declares No Relevant Financial Relationships with Ineligible Companies","article-title":"Tyrosine Kinase Inhibitors. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Majid Moshirfar declares no relevant financial relationships with ineligible companies","author":"Thomson","year":"2025"},{"key":"10.1016\/j.ejphar.2026.179293_bib57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7150\/thno.16767","article-title":"Limited Tumor tissue drug penetration contributes to primary resistance against angiogenesis inhibitors","volume":"7","author":"Torok","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2026.179293_bib58","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/bph.12990","article-title":"Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study","volume":"172","author":"Torok","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179293_bib59","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179293_bib60","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1016\/j.ejmech.2011.05.017","article-title":"Design, synthesis and biological evaluation of novel 4-thiazolidinones containing indolin-2-one moiety as potential antitumor agent","volume":"46","author":"Wang","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.179293_bib61","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10456-012-9291-z","article-title":"Contrasting effects of sunitinib within in vivo models of metastasis","volume":"15","author":"Welti","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ejphar.2026.179293_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s44303-024-00025-3","article-title":"Mass spectrometry imaging for spatially resolved multi-omics molecular mapping","volume":"2","author":"Zhang","year":"2024","journal-title":"Npj Imaging"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926007752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926007752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:09:17Z","timestamp":1789070957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926007752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":62,"alternative-id":["S0014299926007752"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179293","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative assessment of intratumoral sunitinib distribution and therapeutic response in matched primary and metastatic tumor models","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"179293"}}